Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

Inclusion criteria

• biopsy-confirmed esophageal squamous cell carcinoma
• age ≤ 70 years old,
• Karnofsky performance status ≥ 70,
• R0 esophagectomy according to the pathological examination of the resected specimens,
• postoperative stage Ⅱ-Ⅳa according to the AJCC 7th edition of tumor-node-metastasis (TNM) classification for esophageal carcinoma
• Adequate organ functions (1).white blood cell (WBC) ≥3×109⁄L; (2).Absolute neutrophil counts (ANC) ≥1.5×109⁄L; (3).Hemoglobin (Hb) ≥10g⁄dl; (4).Platelet (Plt) ≥100×109⁄L; (5).Total bilirubin <1.5 upper limit of normal (ULN); (6).Aspartate transaminase (AST) ≤2.5 ULN; (7).Alanine aminotransferase (ALT) ≤2.5 ULN; (8).Creatinine ≤1.5 ULN; (9).adequate pulmonary function (FEV1>0.8 L;.
• no previous treatment or severe complications
• Written informed consent

Exclusion criteria

• previous treatment with chemotherapy or radiotherapy
• greater than 3 months after surgery
• complete esophageal obstruction after surgery, esophageal perforation;
• other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years;
• pregnant or breast-feeding women；
• patients with any serious concurrent disease, such as severe diabetes, uncontrolled hypertension, serious chronic obstructive pulmonary disease；
• drug addiction, Alcoholism or AIDS;
• uncontrolled seizures or psychiatric diseases, loss of control over their own behavior;
• with clear chemotherapy drug allergy
• participation in other interventional clinical trials within 30 days;